[On the long-term parenteral corticoid therapy of the asthmatic syndrome with special reference to 6-alpha-fluoro-16-beta-methylprednisolone (betamethasone)].
D000328:Adult; D000368:Aged; D001249:Asthma / Q000188:drug therapy*; D001623:Betamethasone / Q000627:therapeutic use; D001991:Bronchitis / Q000188:drug therapy; D002908:Chronic Disease; D003348:Cortisone / Q000627:therapeutic use; D003907:Dexamethasone / Q000627:therapeutic use; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use; D008875:Middle Aged; D011239:Prednisolone / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D011656:Pulmonary Emphysema / Q000188:drug therapy; D014221:Triamcinolone / Q000627:therapeutic use
D005938:Glucocorticoids; D014221:Triamcinolone; D003907:Dexamethasone; D001623:Betamethasone; D011239:Prednisolone; D003348:Cortisone; D011241:Prednisone; D008775:Methylprednisolone
Zur parenteralen Corticoiddauerbehandlung des asthmatischen Syndroms Unter besonderer Berücksichtigung des 9-alpha-fluoro-16-beta-Methylprednisolon (Betamethason)